CN103961710A - Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation - Google Patents
Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation Download PDFInfo
- Publication number
- CN103961710A CN103961710A CN201410182179.7A CN201410182179A CN103961710A CN 103961710 A CN103961710 A CN 103961710A CN 201410182179 A CN201410182179 A CN 201410182179A CN 103961710 A CN103961710 A CN 103961710A
- Authority
- CN
- China
- Prior art keywords
- dry powder
- adhesion
- powder inhalation
- postoperative joint
- chitin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 20
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 18
- 210000005067 joint tissue Anatomy 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000000399 orthopedic effect Effects 0.000 title abstract 3
- 229920002101 Chitin Chemical class 0.000 claims abstract description 23
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical class [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 20
- 239000003112 inhibitor Substances 0.000 claims abstract description 12
- 238000007873 sieving Methods 0.000 claims abstract description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- 229940098458 powder spray Drugs 0.000 claims description 20
- 206010047163 Vasospasm Diseases 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 3
- 239000005030 aluminium foil Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000715 nimodipine Drugs 0.000 claims description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001289 prazosin Drugs 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- 229960000227 nisoldipine Drugs 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 abstract description 15
- 208000031737 Tissue Adhesions Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 229940010747 sodium hyaluronate Drugs 0.000 abstract description 4
- 229920002521 macromolecule Polymers 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 208000005392 Spasm Diseases 0.000 abstract 2
- 238000005192 partition Methods 0.000 abstract 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 239000011888 foil Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 230000037314 wound repair Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 239000000835 fiber Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 206010058031 Joint adhesion Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000281 joint capsule Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- -1 Chitofilmer Chemical compound 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037873 arthrodesis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medicine, and particularly relates to an anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and a preparation of the anti-adhesion dry powder inhalation. The anti-adhesion dry powder inhalation consists of sodium hyaluronate, chitin derivative, macromolecule partition, and a spasm inhibitor. The preparation comprises the following steps: weighing and mixing the sodium hyaluronate, the chitin derivative, the macromolecule partition, and the spasm inhibitor according to a formula, then grinding the mixture into fine powder, sieving the fine powder with a 200-mesh sieve, then packaging the fine powder with an aluminum foil bag after sieving, and performing ethylene oxide or microwave sterilization so as to obtain the anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues. The anti-adhesion dry powder inhalation has the advantages that ingredients in the medicine are mutually coordinated, the medicine is prepared into dry powder inhalation to be used, obvious functions on aspects of postoperative joint tissue adhesion prevention, wound repair and heal and analgesia are achieved, the quality is stable, the cost is low, the use is convenient, the adhesion to the tissues is good, and clinical operating requirements are met.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the postoperative joint tissue of a kind of orthopaedics anti powder spray and preparation method thereof.
Background technology
Joint accretion refers to periarticular skin, muscle, tendon, and nervus vasculairs etc. change and the dyskinesia that causes.In the tissue of human body, have loose composition and fine and close composition, the former forms joint capsule, muscle conjunctive tissue layer, subcutaneous tissue etc., is all often movable part, and it is netted that the upper collagen fiber of histology and fine-structure mesh fiber do not have, and do not possess certain structure.In contrast, fine and close conjunctive tissue, as the fine and close network structure of formation of sarolemma, aponeurosis (aponeuroses) etc.The cicatrix forming after wound is exactly this tissue.In the therapeutic process of orthopaedics articular trauma, if keep the motion at this place, loose conjunctive tissue is kept existing, if limitation of movement in contrary therapeutic process, fine and close conjunctive tissue propagation, the mobility at impaired place is significantly limited, and this is the mechanism of wound posterior synechiae.In addition adhesion is that the splicing mechanism due to the inertia of modal joint is also identical therewith, and owing to lacking motion, the blood circulation open texture cripetura of slowing down, follows the string, slip and extensibility and the compact tissue that forms.Such process occurs in joint capsule, sarolemma, muscle conjunctive tissue, ligament etc., and causes joint motion limited.Even normal arthrodesis 4 weeks, the adhesion that also can produce certain degree.
In bone surgery, occur that joint accretion is common following three kinds of reasons: the adhesion of (1) wound posterior joint, as knee ligament, meniscus injury etc.; (2) after internal fixation, after Gypsum Fibrosum is fixing, after fixation with small splint.(3) the useless property used joint accretion, as joint of lumbar vertebra adhesion due to long-term bed, hip joint adhesion, Knee Adhesion.
Summary of the invention
According to above the deficiencies in the prior art, the invention provides the postoperative joint tissue of a kind of orthopaedics anti powder spray and preparation method thereof, be used for preventing around arthroscopy, nervous tissue, tissue adhesion after the bone surgery such as tendon repair, have the interior retention time of body long, preventing adhesiving effect acts on significantly.
The postoperative joint tissue of a kind of orthopaedics of the present invention anti powder spray, formed by hyaluronate sodium, chitin derivativ, macromole spacer and vasospasm inhibitor, wherein, the mass ratio of hyaluronate sodium, chitin derivativ, macromole spacer and vasospasm inhibitor is 1:0.3～1:0.1～0.5:0.01～0.1.
Wherein, described chitin derivativ is preferably the one in carboxymethyl chitin, Chitofilmer or succinyl chitin.
Macromole spacer is preferably the one in carboxymethyl cellulose, hydroxypropyl cellulose, dextran, chondroitin sulfate or sodium alginate.
Vasospasm inhibitor is preferably the one in sodium nitroprusside, nisoldipine, nifedipine, nimodipine or prazosin.
The preparation method of anti powder spray for a kind of bone surgery, hyaluronate sodium, chitin derivativ, macromole spacer and vasospasm inhibitor are taken to mixing by above-mentioned formula, then grind to form fine powder, fine powder is crossed to 200 mesh sieves, fine powder packaging of aluminium foil bag after sieving, after ethane via epoxyethane or microwave degerming, obtain the postoperative joint tissue of orthopaedics anti powder spray.
Hyaluronate sodium is a kind of linear polyanionic polysaccharide, and as the necessary material of Human Physiology, it is extensively present in the various tissues of animal, comprises connective tissue, skin, cartilage, vitreum and synovial fluid etc.Hyaluronate sodium molecular weight can reach 4,000,000 to five megadaltons, in aqueous solution, exists with random spiral form, has very large molecule volume, under low concentration, can be woven and penetrate mutually, makes it have specific rheological properties.Hyaluronate sodium prevents that the mechanism of postoperative joint tissue adhesion can be summarized as: (1) forms polymolecular network structure after dissolving, and injured tissue is separated with normal serous coat, plays space obstacle effect and lubrication, reduces friction; (2) suppress hemorrhage and ooze out, reducing the clot quantity that can form permanent adhesion skeleton, Profilin calmness; (3) suppress post-operation inflammatory cell migration and phagocytosis, suppress hematoblastic deposition, promote wound healing; (4) growth and the differentiation of stimulation serous coat cell, make wound serous coat reach physiological reparation.In addition, hyaluronate sodium powder spray is preventing being better than sodium hyaluronate solution and gel aspect tissue adhesion, sodium hyaluronate solution and gel are because concentration is low, molecular weight is little, be absorbed soon in vivo degraded, weaken its iris action at tissue surface, and hyaluronate sodium powder spray is sprayed on after tissue surface, there is a course of dissolution progressively, form high concentration gel in part simultaneously, local viscoelasticity is high and the interior retention time of body is long, forms effective barrier, so its preventing adhesiving effect is remarkable in the serous coat reparation phase.
Chitin derivativ is a kind of chitosan, and the present invention selects the one in carboxymethyl chitin, Chitofilmer or succinyl chitin.Chitin derivativ has good affinity to human body cell, antigenicity is low, safe, at human body injury energy activating cell, a large amount of collagen fiber that produce, collagen fiber can form rapidly careful skin, can scars, and special effect aspect treatment burn, scald, wound, accelerating wound healing, hemostasis, antiinflammatory.The powder spray that chitin derivativ is made has significant effect at prevention of postoperative tissue adhesion, wound healing and ease pain.
The present invention combines hyaluronate sodium with chitin derivativ, then is equipped with macromole spacer and vasospasm inhibitor, and inventor, through lot of experiments, determines three's proportion relation, thereby reaches the maximization that prevents adhesion effect.
The invention has the advantages that: between each composition of medicine, cooperatively interact, and make powder spray use, adhesion between prevention of postoperative joint tissue, wound healing and ease pain have significant effect, and steady quality, cost is low, easy to use, good with the adhesiveness of tissue, meet clinical instructions for use.
Detailed description of the invention
Below in conjunction with embodiment, the present invention will be further described.
Embodiment 1:
A kind of bone surgery anti powder spray, is made up of hyaluronate sodium, carboxymethyl chitin, carboxymethyl cellulose and sodium nitroprusside, and three's mass ratio is 1:1:0.5:0.1.
Embodiment 2:
A kind of bone surgery anti powder spray, is made up of hyaluronate sodium, Chitofilmer, dextran and nimodipine, and three's mass ratio is 1:0.5:0.3:0.05.
Embodiment 3:
A kind of bone surgery anti powder spray, is made up of hyaluronate sodium, succinyl chitin, sodium alginate and prazosin, and three's mass ratio is 1:0.3:0.2:0.02.
Embodiment 1～3 is prepared according to following preparation method, hyaluronate sodium, chitin derivativ, macromole spacer and vasospasm inhibitor are taken to mixing by above-mentioned formula, then grind to form fine powder, fine powder is crossed to 200 mesh sieves, fine powder packaging of aluminium foil bag after sieving, after ethane via epoxyethane or microwave degerming, obtain bone surgery anti powder spray.
Claims (5)
1. the postoperative joint tissue of an orthopaedics anti powder spray, it is characterized in that being formed by hyaluronate sodium, chitin derivativ, macromole spacer and vasospasm inhibitor, wherein, the mass ratio of hyaluronate sodium, chitin derivativ, macromole spacer and vasospasm inhibitor is 1:0.3～1:0.1～0.5:0.01～0.1.
2. the postoperative joint tissue of orthopaedics according to claim 1 anti powder spray, is characterized in that chitin derivativ is the one in carboxymethyl chitin, Chitofilmer or succinyl chitin.
3. the postoperative joint tissue of orthopaedics according to claim 1 anti powder spray, is characterized in that macromole spacer is the one in carboxymethyl cellulose, hydroxypropyl cellulose, dextran, chondroitin sulfate or sodium alginate.
4. the postoperative joint tissue of orthopaedics according to claim 1 anti powder spray, is characterized in that vasospasm inhibitor is the one in sodium nitroprusside, nisoldipine, nifedipine, nimodipine or prazosin.
5. the preparation method of the postoperative joint tissue use of an orthopaedics claimed in claim 1 anti powder spray, it is characterized in that hyaluronate sodium, chitin derivativ, macromole spacer and vasospasm inhibitor to take mixing by above-mentioned formula, then grind to form fine powder, fine powder is crossed to 200 mesh sieves, fine powder packaging of aluminium foil bag after sieving, after ethane via epoxyethane or microwave degerming, obtain the postoperative joint tissue of orthopaedics anti powder spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410182179.7A CN103961710A (en) | 2014-05-04 | 2014-05-04 | Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410182179.7A CN103961710A (en) | 2014-05-04 | 2014-05-04 | Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103961710A true CN103961710A (en) | 2014-08-06 |
Family
ID=51232021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410182179.7A Pending CN103961710A (en) | 2014-05-04 | 2014-05-04 | Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103961710A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166187A (en) * | 1987-06-15 | 1992-11-24 | Centre National De La Recherche | Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their application in human medicine |
| CN1239657A (en) * | 1998-06-24 | 1999-12-29 | 凌沛学 | Antisticking particle and powder containing sodium hyaluronate and their preparation process |
| CN1539514A (en) * | 2003-11-03 | 2004-10-27 | 刘永庆 | Method for preparing multifunctional biological repair material |
| CN1546181A (en) * | 2003-12-12 | 2004-11-17 | 清华大学 | A degradable material for guiding hard tissue regeneration and repair and its preparation method |
| CN1899265A (en) * | 2006-07-08 | 2007-01-24 | 青岛博益特生物材料有限公司 | Medical dust cloud agent or granular agent and its use |
-
2014
- 2014-05-04 CN CN201410182179.7A patent/CN103961710A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166187A (en) * | 1987-06-15 | 1992-11-24 | Centre National De La Recherche | Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their application in human medicine |
| CN1239657A (en) * | 1998-06-24 | 1999-12-29 | 凌沛学 | Antisticking particle and powder containing sodium hyaluronate and their preparation process |
| CN1539514A (en) * | 2003-11-03 | 2004-10-27 | 刘永庆 | Method for preparing multifunctional biological repair material |
| CN1546181A (en) * | 2003-12-12 | 2004-11-17 | 清华大学 | A degradable material for guiding hard tissue regeneration and repair and its preparation method |
| CN1899265A (en) * | 2006-07-08 | 2007-01-24 | 青岛博益特生物材料有限公司 | Medical dust cloud agent or granular agent and its use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6946506B2 (en) | Hydrogel membrane to prevent adhesions | |
| JP6868314B2 (en) | Wound dressing containing hyaluronic acid-calcium and polylysine and its manufacturing method | |
| JP6862441B2 (en) | Hemostatic mixture of cellulosic short and long fibers | |
| Dowling et al. | Determination of efficacy of a novel alginate dressing in a lethal arterial injury model in swine | |
| KR20160009724A (en) | Polymer Foam Composition, Method Of Producing Polymer Foam Using The Same, And Polymer Foam for Packing Therefrom | |
| JP2011508643A (en) | Analgesic apatite calcium phosphate cement | |
| CN111973797B (en) | Non-invasive implantation high-viscosity adhesive material for orthopedics department and preparation method and application thereof | |
| CN104027850A (en) | Postoperative washing agent and preparation method thereof | |
| US9066934B2 (en) | Composite material comprising pectin and calcium phosphate and method for its realisation | |
| CN104906029A (en) | A kind of nasal cavity preparation and its preparation method and application | |
| CN103961710A (en) | Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation | |
| CN103961366A (en) | Anti-adhesion dry powder inhalation for orthopedics department post operation, and preparation of anti-adhesion dry powder inhalation | |
| CN103948623B (en) | A kind of bone surgery anti powder spray and preparation method thereof | |
| CN103948929A (en) | Anti-adhesion powder inhalation applied to orthopedic operation and preparation method of anti-adhesion powder inhalation | |
| CN103961708A (en) | Anti-adhesion dry powder inhaler used after orthopedic surgeries and preparing method thereof | |
| EP1838335A1 (en) | Growth factor composition | |
| CN104645418A (en) | Injectable bone cement and preparation method thereof | |
| CN109568635B (en) | In-situ expansion high-water-absorption hemostatic material and preparation method thereof | |
| Kim et al. | Ultrafine diced rib cartilage graft with minimal incision on chest for rhinoplasty | |
| Arias Fernández et al. | Comparative effect of human and Trypanosoma cruzi calreticulin in wound healing | |
| NZ625851A (en) | Pharmaceutical composition useful for prevention of adhesion or for hemostasis | |
| NZ625851B2 (en) | Pharmaceutical composition useful for prevention of adhesion or for hemostasis | |
| NZ721455B2 (en) | Pharmaceutical composition useful for adhesion prevention or hemostasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140806 |
|
| RJ01 | Rejection of invention patent application after publication |